11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial
Nantia Othonos, Riccardo Pofi, Anastasia Arvaniti, Sarah White, Ilaria Bonaventura, Nikolaos Nikolaou, Ahmad Moolla, Thomas Marjot, Roland H Stimson, André P van Beek, Martijn van Faassen, Andrea M Isidori, Elizabeth Bateman, Ross Sadler, Fredrik Karpe, Paul M Stewart, Craig Webster, Joanne Duffy, Richard Eastell, Fatma Gossiel, Thomas Cornfield, Leanne Hodson, K Jane Escott, Andrew Whittaker, Ufuk Kirik, Ruth L Coleman, Charles A B Scott, Joanne E Milton, Olorunsola Agbaje, Rury R Holman, Jeremy W Tomlinson
Nat Commun. 2023;14:1025. Published:23-Feb-2023. Epub:23-Feb-2023. PMID:36823106. doi:10.1038/s41467-023-36541-w

Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
Moritz J. Hundertmark, Olorunsola F. Agbaje, Ruth Coleman, Jyothis T. George, Rolf Grempler, Rury R. Holman, Hanan Lamlum, Jisoo Lee, Joanne E. Milton, Heiko G. Niessen, Oliver Rider, Christopher T. Rodgers, Ladislav Valkovic, Eleanor Wicks, Masliza Mahmod and Stefan Neubauer
ESC Heart Failure 2021;8:2580-2590. Published:Aug-2021. Epub:06-May-2021. PMID:33960149. doi:10.1002/ehf2.13406

A Proof of Concept Study to Evaluate the Impact of an Established Telehealth Mood Monitoring System on Mood in Individuals with Type 2 Diabetes when Initiating an Injectable Therapy
Hermione Price, Olorunsola F. Agbaje, Jonathan Price, Guy M Goodwin, John Geddes, Rury R. Holman
J Diab Metab. 2020;11:1-7. Published:28-Oct-2020. doi:10.35248/2155-6156.20.11.857

Predicting Post One-year Durability of Glucose-lowering Monotherapies in Patients with Newly-diagnosed Type 2 Diabetes Mellitus - A MASTERMIND Precision Medicine Approach (UKPDS 87)
Olorunsola F. Agbaje, Ruth L. Coleman, Andrew T. Hattersley, Angus G. Jones, Ewan R. Pearson, Beverley M. Shields, and Rury R. Holman, for the MASTERMIND consortium
Diabetes Res Clin Pract. 2020;166:108333. Published:Aug-2020. Epub:20-Jul-2020. PMID:32702468. doi:10.1016/j.diabres.2020.108333

Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients
Chitrabhanu Ballav, Archana Dhere, Irene Kennedy, Olorunsola F. Agbaje, Sarah White, Rachel Franklin, Bolette Hartmann, Jens J. Holst, Rury R. Holman, Katharine R. Owen
Endocrinol Diab Metab. 2020;3:e00130. Published:Jul-2020. Epub:12-Jun-2020. PMID:327045. doi:10.1002/edm2.130

Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86)
Ernesto Maddaloni, Ruth L. Coleman, Olorunsola F. Agbaje, Raffaella Buzzetti, Rury R. Holman
Lancet Diabetes Endocrinol 2020;8:206-15. Published:Mar-2020. Epub:04-Feb-2020. PMID:32032540. doi:10.1016/S2213-8587(20)30003-6

Simulating the impact of targeting lower systolic blood pressure and LDL-cholesterol levels on type 2 diabetes complication rates
Mostafa SA, Coleman RL, Agbaje OF, Gray A, Holman RR, Bethel MA
J Diabetes Complications 2019;33:69-74. Published:Jan-2019. Epub:10-Oct-2018. PMID:30361000. doi:10.1016/j.jdiacomp.2018.09.017

Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with Type 2 diabetes and cardiovascular disease
S. A. Mostafa, R. L. Coleman, O. F. Agbaje, A. M. Gray, R. R. Holman and M. A. Bethel
Diabet Med. 2018;35:72-77. Published:Jan-2018. Epub:23-Oct-2017. PMID:29057545. doi:10.1111/dme.13533